New YorkBristol Myers Squibb licensed 12 Hengrui drug programs.
Western pharma is buying pre-validated programs from China’s labs rather than running early discovery in-house.
The deal reaches $15.2 billion at full milestones; Hengrui retains domestic rights for 4 Bristol immunology drugs.
Sources: STAT
THE OLD MODEL
For decades, Big Pharma ran early discovery in-house — medicinal chemistry, target validation, lead optimization — then licensed Chinese and Indian generics for off-patent manufacturing. China's role was downstream: low-cost APIs, contract manufacturing, occasional clinical trial sites.
WHAT CHANGED
Beginning around 2015, China overhauled its drug regulator and joined the ICH (International Council for Harmonisation), which standardizes clinical trial data so it's accepted by the FDA and EMA. Chinese biotechs could suddenly run trials whose results Western regulators would credit — collapsing the duplication tax that had kept discovery onshore.
THE COST ASYMMETRY
A medicinal chemist in Shanghai costs roughly a quarter of one in Cambridge, Massachusetts. A Phase I trial in China runs at a fraction of US cost and enrolls faster — large, treatment-naive patient populations and centralized hospital systems. Running a discovery program in China to a clinical proof-point and then licensing it West is now cheaper than running the same program in-house.
WHY BIG PHARMA NEEDS THIS
The patent cliff is real: roughly $200bn of branded pharma revenue loses exclusivity between 2025 and 2030, including Keytruda, Eliquis, and several Bristol Myers blockbusters. In-house pipelines aren't replacing it fast enough. Buying validated Chinese assets is the cheapest way to refill the shelf before the cliff hits.
THE GEOPOLITICAL FRICTION
The BIOSECURE Act, which passed the US House in 2024, would bar federal contracts with named Chinese biotech firms (notably WuXi AppTec and BGI) on national-security grounds — patient genetic data, supply-chain dependency. Discovery licensing deals like Bristol-Hengrui are structured to avoid the prohibited services (no patient data transfer, just molecule rights), but the political wind is against deepening this dependency.
WHAT HENGRUI KEPT
Retaining domestic China rights on 4 of the 12 programs is the standard structure now: the Chinese originator keeps the world's second-largest pharma market for itself, monetizing the rest of the world via the Western partner's regulatory and commercial muscle. It's the inverse of the colonial pharma model — the Western firm becomes the distribution arm for an Asian discovery engine.